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Abstract
This study aimed to evaluate the safety and efﬁcacy of vitamin K antagonist (VKA) in atrial ﬁbrillation (AF) patients with previous ulcer
bleeding.
In this multicenter, retrospective analysis, clinical outcomes of 754 AF patients with a history of ulcer bleeding were evaluated. After
ulcer treatment, 458 patients (61%) were treated with VKA, and the outcomes were compared to 296 patients (39%) without VKA.
VKA treatment signiﬁcantly increased major bleeding (7.3%/year vs 3.2%/year, P<0.001), and reduced major adverse cardiac
events (MACE) (5.4%/year vs 10.0%/year, P<0.001). Speciﬁcally, risk of gastrointestinal bleeding was signiﬁcantly higher in the VKA
group than no-VKA group (5.7%/year vs 2.6%/year, P<0.001). Consequently, there was no difference in the incidence of composite
of a MACE and major bleeding, between the 2 groups. In patients with time in the therapeutic range (TTR) ≥65%, VKA signiﬁcantly
decreased MACE (2.8%/year vs 10.0%/year, P<0.001) without increasing major bleeding. Net clinical beneﬁt model showed
beneﬁcial effects of VKA in patients with TTR ≥65%, and harmful effects in those with TTR<55%.
In AF patients with previous ulcer bleeding, VKA treatment did not improve clinical outcomes unless the international normalized
ratio level was constantly maintained (TTR ≥65%), as the gastrointestinal bleeding (GIB) risk signiﬁcantly increased.
Abbreviations: AF = atrial ﬁbrillation, GIB = gastrointestinal bleeding, NCB = net clinical beneﬁt, SCE = signiﬁcant clinical event,
VKA = vitamin K antagonist.
Keywords: atrial ﬁbrillation, hemorrhage, oral anticoagulant, stroke, vitamin K antagonistEditor: Yutang Wang.
Funding: This study was supported by a CMB-Yuhan research grant of Yonsei
University College of Medicine for (6-2015-0173), research grants from the Basic
Science Research Program through the National Research Foundation of Korea
funded by the Ministry of Education, Science and Technology (NRF-
2012R1A2A2A02045367), and a grant from the Korean Healthcare technology
R&D project funded by the Ministry of Health & Welfare (HI16C0058,
HI15C1200).
S-JL, J-HS, and J-BK contributed equally to this work.
The authors have no conﬂicts of interest to disclose.
Supplemental Digital Content is available for this article.
a Division of Cardiology, Yonsei University College of Medicine, Seoul, b Division of
Cardiology, Bundang CHA Medical Center, CHA University, Seongnam, c Division
of Cardiology, Kyung Hee University College of Medicine, Seoul, d Division of
Cardiology, Yonsei University Wonju College of Medicine, Wonju, e Division of
Cardiology, Sanggye Paik Hospital, Inje University College of Medicine, f Division
of Cardiology, Gangnam Severance Hospital, Seoul, Republic of Korea.
∗
Correspondence: Boyoung Joung, Yonsei University College of Medicine, 50
Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea (e-mail:
cby6908@yuhs.ac); Jong-Yun Kim, Department of Cardiology, Gangnam
Severance Hospital, Yonsei University College of Medicine, 612 Eonju-ro,
Gangnam-gu, Seoul 135-720, Republic of Korea (e-mail: jykim0706@yuhs.ac).
Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All
rights reserved.
This is an open access article distributed under the Creative Commons
Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Medicine (2016) 95:47(e5467)
Received: 24 April 2016 / Received in ﬁnal form: 31 October 2016 / Accepted:
31 October 2016
http://dx.doi.org/10.1097/MD.0000000000005467
11. Introduction
Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia, with an overall prevalence of 5.5%, and the
incidence increases up to 17.8% in individuals aged 85 years or
older.[1] Because patients with AF have a 5-fold greater risk of
ischemic stroke,[2] appropriate anticoagulation is the main goal
of treatment in patients with high risk.[3] Vitamin K antagonists
(VKAs) are highly effective for stroke prevention,[4] which are
recommended in all AF patients with a stroke risk, even in
patients with intermediate risk.[5] However, VKA also increase
the risk of fatal bleeding in some AF patients with concomitant
risk factors,[6–8] or previous bleeding history.[9] Therefore,
when estimating the clinical beneﬁt of anticoagulation in AF
patients, safety issue should be carefully addressed, as well as
their efﬁcacy.[10,11] Bleeding from the upper gastrointestinal
tract is most common,[12] which negates the beneﬁcial effect of
VKA.[13] The main cause of upper gastrointestinal bleeding
(GIB) is peptic ulcer. The incidence of peptic ulcer bleeding
ranges from 20 to 60 per a population of 100,000, which is
increasing due to the use of antithrombotic agents and
nonsteroidal antiinﬂammatory drugs (NSAIDs).[14] Although,
proton pump inhibitors (PPIs) and Helicobacter pylori
eradication have led to the successful treatment of acute ulcer
bleeding,[15] the long-term use of oral anticoagulation therapy
signiﬁcantly increases the risk of GIB in patients with previous
ulcers.[16,17] In this retrospective, multicenter study we
evaluated the long-term safety and efﬁcacy of VKA treatment
in AF patients with previous ulcer bleeding.
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2.1. Study population and data collection
This was a multicenter, retrospective study conducted at 6
referral centers in South Korea. The study protocol was approved
by the Institutional Review Board of all participating institutions
and complied with the Declaration of Helsinki. We enrolled 754
AF patients admitted to these centers from January 2000 to
December 2013, who were hospitalized with the diagnosis of
peptic ulcer bleeding during that period. Patients were eligible for
analysis if they were diagnosed with AF (ICD-9 code 427.31) and
had a peptic ulcer (ICD-9 codes 533.0–533.9) with active
bleeding, visible blood vessels, or adherent clots that were
successfully treated by endoscopic and medical therapy. Patients
with other GI pathologic lesions, including Mallory–Weiss tears,
angiodysplasia or Dieulafoy lesions were not included in this
study. We also did not include patients with a low stroke risk
(CHA2DS2-VASc score 0 to 1), concomitant mitral stenosis, or
prosthetic heart valves (ICD-9 codes 394.0, 394.2, 396.0, 396.1,
396.8, V43.3, or V42.4), previous valvular surgery (ICD-9 codes
35.10–35.14 or 35.20–35.28), evidence of renal/hepatic failure,
malignancy, previous intracerebral hemorrhage, and insufﬁcient
clinical data. Among the patients who were treated with VKAs
after the ulcer treatment, those who had skipped the VKA for
more than 1 month for any cause were not included in this study.
The patients’ medical records were reviewed for information on
the age, gender, weight, comorbidities, medication use, CHADS2
(congestive heart failure, hypertension, age, diabetes mellitus,
prior stroke or transient ischemic attack [doubled]), CHA2DS2-
VASc (congestive heart failure, hypertension, age ≥75 [doubled],
diabetes mellitus, prior stroke, or transient ischemic attack
[doubled]-vascular disease, age 65–74 years and sex category
[female]) and HAS-BLED (hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition, labile INR,
elderly [>65], drugs/alcohol concomitantly) score. The efﬁcacy
endpoint included a major adverse cardiac events (MACE)
composite endpoint, comprised of any cause of death, ischemic
strokes, and myocardial infarctions. The safety outcome was
major bleeding, which was deﬁned as follows: any central
nervous system (CNS) bleeding which included an intracerebral
hemorrhage (ICH), subarachnoid hemorrhage (SAH), subdural
hemorrhage (SDH), or epidural hemorrhage (EDH); gastric/
duodenal bleeding that required a transfusion of at least 2units of
red blood cells or the equivalent of whole blood over 24hours.
We deﬁned a signiﬁcant clinical event (SCE) as the ﬁrst major
event that occurred during the follow-up period including
MACE, major bleeding episode, or death. When a patient
experienced both MACE and major bleeding events during the
period, each event was counted respectively. However, when we
analyzed the Kaplan–Meier cumulative SCE-free survival, we
counted the ﬁrst event only.2.2. Intensity of anticoagulation
In patients with concomitant indications for VKA treatment, the
decision was made by the physicians’ clinical evaluation of the
risk for thrombotic and hemorrhagic events. Among the 754
patients enrolled in this study, 458 (61%) were treated with VKA
during the follow-up period. The intensity of the anticoagulation
was determined by the INR values. The INR values at each
outpatient clinic/emergency department visit and during hospital
admission were retrieved from the medical records. Data on the
ﬁrst 4 weeks after initiation of the VKA therapy were excluded2from the analysis. The mean INR values and time in the
therapeutic range (TTR) of an INR of 2.0 to 3.0 were calculated
using the linear interpolation methods proposed by Rosendaal
et al.[18] This method assumes that the INR values between 2
consecutive measurements vary linearly.2.3. Net clinical beneﬁt assessment
The net clinical beneﬁt (NCB) was assessed by calculating the
difference in the annualized incidence rate (IR) of MACE and
major bleeding multiplied by a weighting factor. We adopted the
weighting factor derived from the ACTIVE trial[13] that
measured the adjusted hazard ratio (HR) for death after the
event standardized to the adjusted HR of ischemic strokes (IS,
weight 1.0). The relative weight for each clinical event was 3.08
for hemorrhagic stroke (HS), which included ICHand SAH, 0.60
for other CNS bleeding (Other-CNS) that included SDH and
EDH, and 0.67 for extracranial bleeding, respectively. As a
result, we calculated the NCB according to the following
equation:
NCB ¼ ½IRISno VKA þ 3:08  IRHSno VKA þ 0:60
 IROtherCNSno VKA þ 0:67  IRExtracranialno VKA½IRISVKA
þ 3:08  IRHSVKA þ 0:60  IROtherCNSVKA þ 0:67
 IRExtracranialVKA
The resulting values were regarded as ischemic stroke
equivalents prevented by VKA per 100 patient-years.2.4. Statistical analysis
Continuous variables such as age or ulcer size were expressed as
means± standard deviation (SD) and compared by Student t test.
Categorical variables such as sex or medication status were
reported as the absolute number or percentage and analyzed by
Fisher exact test or Pearson x2 test. Incidence rates of outcome
events are presented as linearized rates (event rates for 100
person-years of follow-up), and were compared using a mid-P
exact test. Survival free from MACE or major bleeding events
between patients with and without VKA was analyzed by the
Kaplan–Meier method, and comparisons were made by log-rank
test. The risk of MACE, major bleeding, or their composite
outcomes associated with VKA treatment was estimated by
means of Cox proportional hazard models, with adjustment for
CHA2DS2-VASc or HAS-BLED scores. All the analyses were
performed using the SPSS statistical package (SPSS, Inc., Chicago,
IL) version 19.0. A P-value less than 0.05 was considered
statistically signiﬁcant.3. Results
3.1. Characteristics of the study population
Clinical characteristics of patients with (VKA group) or
without (no-VKA group) VKA are presented in Table 1. The
mean follow-up duration was 3.5±2.4 years in the VKA group,
and 3.2±2.2 years in the no-VKA group, respectively (P=0.08).
The ratio of a female gender, hypertension, and heart failure was
higher in patients with VKA. The VKA group had higher
CHADS2, CHA2DS2-VASc, andHAS-BLED scores. Importantly,
the proportion of high risk patients for a stroke (CHADS2 ≥3) or
bleeding (HAS-BLED ≥3) was signiﬁcantly higher in the VKA
group. There was no difference in the location, size, and
Table 1
Patient characteristics.
Characteristic VKA (n=458) No VKA (n=296) P
Age, y 68.4±10.6 68.8±10.4 0.60
Female, n (%) 210 (46%) 105 (36%) 0.005
Atrial ﬁbrillation type 0.03
Permanent 226 (49%) 140 (47%) 0.58
Persistent 103 (23%) 90 (30%) 0.02
Paroxysmal 129 (28%) 66 (22%) 0.04
Hypertension 359 (78%) 213 (72%) 0.04
Diabetes mellitus 200 (44%) 114 (39%) 0.16
Heart failure 187 (41%) 94 (32%) 0.01
History of a stroke/transient
ischemic attack
174 (38%) 83 (28%) 0.005
Location of the ulcer 0.98
Gastric ulcer 251 (55%) 161 (54%)
Duodenal ulcer 118 (26%) 76 (26%)
Both 89 (19%) 59 (20%)
Endoscopic stigmata of bleeding 0.72
Active bleeding 156 (34%) 104 (35%)
Visible vessel 202 (44%) 115 (39%)
Adherent clot 101 (22%) 77 (26%)
Mean size of the ulcer, cm 1.15±0.74 1.23±0.81 0.16
Large ulcer (≥2cm) 92 (20%) 65 (22%) 0.54
CHADS2 2.71±1.10 2.30±1.15 <0.001
1 36 (8%) 74 (25%) <0.001
2 201 (44%) 127 (43%) 0.79
3–6 221 (48%) 95 (32%) <0.001
CHA2DS2-VASc 4.13±1.43 3.54±1.45 <0.001
HAS-BLED 3.73±1.78 3.32±1.76 0.002
0–2 127 (28%) 118 (40%) <0.001
≥3 331 (72%) 178 (60%)
Concomitant medications
Antiplatelet agent 137 (30%) 142 (48%) <0.001
Nonsteroidal antiinﬂammatory
drug
129 (28%) 74 (25%) 0.35
Proton pump inhibitor 307 (67%) 170 (58%) 0.008
H2 receptor antagonist 249 (54%) 162 (55%) 0.88
Mean values± standard deviation or the number and percentage of patients.
CHADS2= congestive heart failure, hypertension, age ≥75, diabetes mellitus, and prior stroke or
transient ischemic attack; CHA2DS2-VASc= congestive heart failure, hypertension, age ≥75
(doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled)-vascular disease, age
65–74 years, and sex category (female), HAS-BLED=hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile INR, elderly (>65), drugs/alcohol concomitantly,
VKA= vitamin K antagonist.
Table 2
Comparison of the clinical events during the follow-up period accord
Total
(n=458) P
∗
Composite of death, ischemic strokes and myocardial infarctions 92 (5.42) <0.001
Major bleeding 123 (7.31) <0.001
Gastric/duodenal bleeding 95 (5.65) <0.001
Hemorrhagic stroke (ICH, SAH) 13 (0.77) 0.06
Other CNS bleeding (SDH, EDH) 15 (0.89) 0.16
Signiﬁcant clinical event 187 (11.20) 0.35
The numbers in parentheses represent event rates for 100 person-years.
CNS= central nervous system, EDH=epidural hemorrhage, ICH= intracerebral hemorrhage, SAH= su
antagonist.
∗
P-value versus no-VKA group.
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3characteristics of the ulcer lesions between the 2 groups. The
prescription rate of antiplatelet agents was higher in the no VKA
group (30% vs 48%, P<0.001), and the rate of PPIs was higher
in the VKA group (67% vs 58%, P=0.008), respectively. The
indications for antiplatelet treatment in the no-VKA group
included stroke prevention (n=85, 60%), ischemic heart disease
(n=43, 30%), and a history of a thrombosis (n=14, 10%).
However, in the patients with VKA, the most common cause of
antiplatelet therapy was ischemic heart disease (n=86, 63%).3.2. Outcome analyses
The incidences ofMACE, bleeding events, and composite of these
2 outcomes according to the VKA treatment are presented in
Table 2. VKA treatment signiﬁcantly increased the risk of major
bleeding (7.3%/year vs 3.2%/year, P<0.001), while it reduced
the risk of MACE (5.4%/year vs 10.0%/year, P<0.001). There
was a signiﬁcant difference in the cumulative survival free from
MACE (Fig. 1A, log rank P<0.001), and major bleeding
(Fig. 1B, log rank P<0.001) according to the VKA prescription.
Especially, a risk of GIB was signiﬁcantly higher in the VKA-
treated group compared to the no-VKA group (5.7%/year vs
2.6%/year, P<0.001), while the risk of HSs (P=0.06) and other
CNS bleeding (P=0.16) was not signiﬁcantly increased.
Consequently, there was no difference in the incidence of an
SCE, which was a composite of MACE and major bleeding,
between the 2 groups (11.2%/year vs 12.9%/year, P=0.35).
Also, the Kaplan–Meier cumulative survival free from an SCE
was not different (Fig. 1C, log rank P=0.24). We then compared
the clinical outcomes of the patients with VKA according to their
mean TTR level, which was calculated by the Rosendaal method.
A protective effect of VKA against MACE was not observed in
the VKA group patients with a mean TTR of<55% (12.1%/year
vs 10.0%/year, P=0.34, and Fig. 2A). Further, those with amean
TTR of ≥65% did not show any higher risk of major bleeding
(3.4%/year vs 3.2%/year, P=0.98, and Fig. 2B), including
GIB (2.0%/year vs 2.6%/year, P=0.41). Contrarily, the
incidence of GIB was much higher in the patients with a mean
TTR of <55% compared to the no-VKA group (12.9%/year vs
2.6%/year, P<0.001), which resulted in a markedly increased
risk of major bleeding (15.2%/year vs 3.2%/year, P<0.001, and
Fig. 2B). Moreover, the risk of HSs was also signiﬁcantly
increased in the patients with a mean TTR of <55% (1.7%/year
vs 0.2%/year, P=0.01). As a result, among the VKA grouping to the VKA treatment.
VKA (n=458)
No VKA
(n=296)
TTR<55
(n=109) P
∗
TTR 55–65
(n=224) P
∗
TTR≥65
(n=125) P
∗
38 (12.07) 0.34 40 (4.68) <0.001 14 (2.79) <0.001 92 (10.01)
46 (15.19) <0.001 60 (6.84) <0.001 17 (3.38) 0.98 31 (3.18)
39 (12.88) <0.001 46 (5.25) <0.001 10 (1.99) 0.41 25 (2.56)
5 (1.65) 0.01 5 (0.57) 0.23 3 (0.59) 0.29 2 (0.22)
2 (0.66) 0.58 9 (1.03) 0.13 4 (0.80) 0.41 4 (0.41)
59 (20.89) 0.004 101 (12.40) 0.69 27 (5.43) <0.001 118 (12.89)
barachnoid hemorrhage, SDH= subdural hemorrhage, TTR= therapeutic range, VKA= vitamin K
Figure 1. Kaplan–Meier estimates for (A) the survival free from MACE, (B) major bleeding, or (C) signiﬁcant clinical events.
Lee et al. Medicine (2016) 95:47 Medicinepatients, those with a mean TTR of <55% had an increased risk
of an SCE compared to the no-VKA group (20.9%/year vs
12.9%/year, P=0.004 and Fig. 2C), while those with a mean
TTR of ≥65% had a decreased risk (5.4%/year vs 12.9%/year,
P<0.001, and Fig. 2C). In the VKA group, patients with a TTR
of 55% to 65%, the risk of an SCE did not differ (12.4%/year vs
12.9%/year, P=0.69, and Fig. 2C) because the increased
bleeding risk negated the beneﬁcial effect of MACE reduction.
Table 3 shows the results from the Cox regression analyses.
VKA treatment was associatedwith a lower risk ofMACE only in
patients with a TTR of ≥55% (TTR ≥65%: HR 0.22 [95% CI,
0.12–0.38]; TTR 55–65%: HR 0.38 [95% CI, 0.28–0.50]).
Further, the risk of major bleeding was associated with VKA
treatment in those with a TTR<65% (TTR<55–65%: HR 2.03
[95% CI, 1.31–3.16]; TTR <55%: HR 4.42 [95% CI,
2.77–7.07]). Considering MACE and major bleeding together,
VKA treatment increased the risk of SCE in the TTR <55%
group (HR 1.37 [95%CI, 0.99–1.87]), while it mitigated the risk
in the TTR ≥65% group (HR 0.32 [95% CI, 0.21–0.49]).
Patients with a TTR of 55% to 65%, did not beneﬁt from the
VKA treatment (P=0.22).3.3. Net clinical beneﬁt assessment
Figure 3 presents the NCB of the VKA treatment using the NCB
model that weighs ischemia or hemorrhage events by the HR for
death after the event.[13] We compared the NCB according to the
risk group for the CHADS2 and HAS-BLED scores. VKA
treatment had a positive NCB in the patients with a CHADS2 ≥3,
which reduced 1.55 ischemic stroke equivalents per 100 patientFigure 2. Kaplan–Meier estimates for (A) the survival free from MACE, (B) major ble
(TTR) values.
4years (95% CI, 0.53–2.87). However, it had no beneﬁt for a
CHADS2 score of 1 to 2. Among patients with CHADS2 ≥3,
those with concomitant high bleeding risk (HAS-BLED ≥3) did
not show a positive NCB by VKA treatment, while those with
HAS-BLED <3 showed a positive NCB by reduction of 4.41
ischemic stroke equivalents per 100 patients years (95% CI,
1.70–7.12). Furthermore, VKA treatment was shown to be
harmful by increasing 2.76 ischemic stroke equivalents per 100
patient years (95% CI, 0.85–4.70) in patients with a HAS-BLED
score of ≥3. No NCB was observed when all of the VKA group
patients were compared to the no-VKA group. We also
investigated the NCB of the VKA treatment according to their
mean TTR values. With respect to the NCB, VKA treatment was
shown to be beneﬁcial in those with a TTR of ≥65% (decreased
the ischemic stroke equivalents by 5.14 per 100 patient years,
95%CI, 2.07–8.20), while it was harmful in those with a TTR of
<55% (increased the stroke equivalents by 10.33, 95% CI
4.51–14.9). AnNCBwas not observed in the patients with a TTR
of 55% to 65%.
3.4. Bleeding risk in patients with previous ulcer bleeding
on VKA treatment
We calculated the bleeding risk of AF patients with previous ulcer
bleeding on VKA treatment. Compared to the no-VKA group,
VKA treatment signiﬁcantly increased the risk of major bleeding
by 2.7%/year (95% CI, 0.20–5.16, P=0.04, Fig. 4) in patients
with a HAS-BLED score of <3, and by 4.4%/year (95% CI,
1.87–6.89, P=0.002) in those with a HAS-BLED score ≥3.
Bleeding risk was not signiﬁcantly increased by coprescription ofeding, or (C) signiﬁcant clinical events according to the time in therapeutic range
Table 3
Risk of a MACE and major bleeding events associated with VKA treatment in AF patients with GI ulcers.
Event rate per 100 person-years Unadjusted HR P Adjusted HR P
Major adverse cardiac events
VKA, TTR ≥65 2.99 0.28 (0.16–0.49) <0.001 0.22 (0.12–0.38)
∗
<0.001
VKA, TTR 55–65 4.80 0.53 (0.40–0.71) <0.001 0.38 (0.28–0.50)
∗
<0.001
VKA, TTR <55 12.07 1.15 (0.79–1.68) 0.47 1.12 (0.76–1.64)
∗
0.58
No VKA 9.94
Major bleeding
VKA, TTR ≥65 3.39 1.03 (0.57–1.85) 0.82 0.97 (0.53–1.76)† 0.91
VKA, TTR 55–65 6.84 2.24 (1.51–3.33) <0.001 2.03 (1.31–3.16)† 0.002
VKA, TTR <55 15.50 4.56 (2.89–7.19) <0.001 4.42 (2.77–7.07)† <0.001
No VKA 3.18
Composite outcome of MACE and major bleeding
VKA, TTR ≥65 5.43 0.41 (0.27–0.62) <0.001 0.32 (0.21–0.49) ‡ <0.001
VKA, TTR 55–65 12.40 0.87 (0.69–1.10) 0.24 0.85 (0.65–1.11) ‡ 0.22
VKA, TTR <55 21.90 1.56 (1.14–2.13) 0.006 1.37 (0.99–1.87) ‡ 0.04
No VKA 13.10
AF= atrial ﬁbrillation, GI=gastrointestinal, HR=hazard ratio, MACE=major adverse cardiac events, TTR= therapeutic range, VKA= vitamin K antagonist.
∗
Adjusted for the CHA2DS2-VASc score.
† Adjusted for the HAS-BLED score.
‡ Adjust for the CHA2DS2-VASc and HAS-BLED score.
Lee et al. Medicine (2016) 95:47 www.md-journal.comantiplatelet agent with VKA (Supplementary Fig. 1a, http://links.
lww.com/MD/B424 log rank P=0.27). Increased bleeding risk
by VKA treatment was also noted in patients with PPI
prescription (Supplementary Fig. 1b, http://links.lww.com/MD/
B424, log rank P=0.004). The overall bleeding risk of the HAS-
BLED<3 group (mean HAS-BLED score 1.37±0.65) was 3.5%/
year (95% CI, 2.34–5.01), which was signiﬁcantly higher than
the risk in those with a HAS-BLED score of 2 included in the
Euro Heart Survey[6] (1.9%/year, RR 1.85, 95% CI 0.98–3.51,
P=0.05) and Japanese AF patients with HAS-BLED score of 2[19]
(1.0%/year, RR 2.46, 95% CI, 1.15–3.77, P<0.001).
4. Discussion
This multicenter retrospective study investigated the long-term
safety and efﬁcacy of VKA treatment in AF patients with previous
ulcer bleeding who were indicated for anticoagulation due to
their stroke risk. Between the patients treated with VKA and
those without, there was no difference in the incidence of SCEs
requiring hospitalization, because the incidence of GIB wasFigure 3. Net clinical beneﬁt of the VKA treatment according to the risk group
and time in the therapeutic range (TTR). Values represent ischemic stroke
equivalents prevented per 100 patient-years by the VKA treatment.
5signiﬁcantly increased by the VKA treatment, even if it mitigated
a stroke incidence. We also estimated the NCB of VKA by
weighting each clinical event by their hazard for death or
disability.[13] Patients with a CHADS2 score of 1 and 2, who were
indicated for anticoagulation with an annual stroke risk of 2.8%
and 4.0%, respectively, did not beneﬁt from the use of VKAs as
the signiﬁcantly increased GIB risk invalidated the beneﬁt.
Furthermore, VKA signiﬁcantly increased the major bleeding
incidence in a relatively low bleeding risk group (HAS-BLED
score 0–2) by increasing the GIB risk. The incidence was much
higher compared to the general AF patients with a HAS-BLED
score of 2 included in the EuroHeart Survey and Japanese cohort.Figure 4. Annual incidence of major bleeding events between patients with
and without VKA treatment stratiﬁed by a HAS-BLED score of 3.
[3] Camm AJ, et al. European Heart Rhythm Association; European
Lee et al. Medicine (2016) 95:47 MedicineThis ﬁnding implies that previous peptic ulcers might be a long
lasting risk factor for GIB in patients on VKA. Further, when we
analyzed the outcomes in the VKA group patients according to
the mean TTR value, the beneﬁt of VKAs varied according to the
value. VKA treatment could not attenuate the ischemic stroke risk
in those with a TTR of <55%, while increasing GIB and a major
bleeding risk. Consequently, VKA treatment had a negative NCB
in the VKA group patients with a TTR of <55% as compared to
the no-VKA group. In the TTR ≥65% group, however, the major
bleeding risk did not rise, while the MACE risk distinctly
decreased with VKA, which led to a favorable NCB in this group.
This ﬁnding was in line with the previous reports that the quality
of anticoagulation is strongly correlatedwith the clinical outcome
of AF patients,[20,21] and the importance is more prominent in
this higher risk group for bleeding. It would be plausible to
improve the quality of anticoagulation by providing satisfactory
education,[22] utilizing self-monitoring strategies,[23,24] and
computer-assisted dosage determinations.[25] Recently, new oral
anticoagulants (NOACs) are widely being used in AF patients due
to their superior or noninferior efﬁcacy and safety compared to
VKAs.[26–28] However, there is serious concerns about the safety
of NOACs in relation to GI bleeding issues.[29] Compared to
warfarin, dabigatran (150mg twice daily) was associated with an
increased risk of major GIB[30] (RR 1.49, 95% CI, 1.21–1.84),
and rivaroxaban (20mg daily) was also associated with an
increased risk of major GIB[31] (RR 1.61, 95% CI, 1.30–1.99).
Additionally, 50% of GIB with dabigatran 150mg twice daily
met the criteria of life-threatening bleeding.[29] In this regard,
VKA treatment with a high quality could be an appropriate
treatment strategy until an optimal NOAC selection and the dose
can be elucidated in AF patients with previous ulcer.
4.1. Limitations
There were several limitations to this study. This was a
retrospective study and not a randomized trial, and it carried
all the limitations of such trials, despite this being a multicenter
study. The data abstracted from the medical records were limited
by the degree of the documentation. Hence, the indication for
VKA treatment and the reason for an omission were ambiguous
in some patients. Furthermore, the decision for a VKA
prescription was dependent on the physician of each center,
which could have inﬂuenced the consistency of our results.
5. Conclusions
In AF patients with a previous ulcer history, VKA treatment did
not improve the clinical outcome unless the INR level was
constantly maintained (TTR≥65), because the GIB risk
signiﬁcantly increased during the long-term follow-up. Our
study shows that GI bleeding history can be a long-lasting risk
factor for rebleeding by VKA treatment. Also, our ﬁnding
reafﬁrms the importance of maintaining optimal INR level in
reducing bleeding risk as well as preventing ischemic strokes. AF
patients with GI bleeding history should be paid particular
attention, when treated with VKA due to their bleeding risk.
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